市場調査レポート
商品コード
1233005

カスタム抗体の世界市場:サービス別・種類別・供給源別・用途別・適応症別・エンドユーザー別の将来予測 (2028年まで)

Custom Antibody Market by Service, Type, Source, Application, Indication, End User - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 278 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
カスタム抗体の世界市場:サービス別・種類別・供給源別・用途別・適応症別・エンドユーザー別の将来予測 (2028年まで)
出版日: 2023年02月28日
発行: MarketsandMarkets
ページ情報: 英文 278 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のカスタム抗体の市場規模は、2023年の5億4,800万米ドルから2028年には8億6,000万米ドルに達すると予測され、予測期間中のCAGRは9.4%となります。

ADC開発向け投資の増加や、カスタム抗体の構造ベースドラッグデザインや治療用mAbの研究拡大などの要因が、市場の成長を加速させています。

種類別では、組換え抗体のセグメントが予測期間中 (2023年~2028年) に最も高いCAGRで成長すると予測されています。その要因として、組換え抗体の免疫原性の低さや、研究の再現性の向上などが挙げられます。

供給源別では、マウスのセグメントが2023年に圧倒的なシェアを占め、今後も急速に成長すると見込まれています。マウスは、研究目的のモノクローナル抗体の生産において、以前より好ましい宿主とされており、そのため今後も急速に成長すると見込まれています。

用途別では、2022年には研究用途が圧倒的なシェアを占めています。研究・創薬におけるカスタム抗体の採用は、市場成長を予測する主要な要因の1つです。

適応症別では、腫瘍分野が2022年時点で圧倒的なシェアを占め、予測期間中 (2023年~2028年) に最も高いCAGRで成長する見通しです。

地域別に見ると、2022年には北米が圧倒的なシェアを占める一方、アジア太平洋が急速に成長するものと思われます。

当レポートでは、世界のカスタム抗体の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、サービス別・種類別・供給源別・用途別・適応症別・エンドユーザー別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • バリューチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 特許分析
  • 価格分析
  • 技術分析
  • 規制状況
  • 主な会議とイベント (2023年)
  • 主な利害関係者と購入基準
  • 顧客のビジネスに影響を与える動向/混乱

第6章 カスタム抗体市場:サービス別

  • イントロダクション
  • 抗体開発
    • 抗体の特性評価
    • 抗原調製
    • 予防接種・ハイブリドーマ生産
  • 抗体産生・精製
  • 抗体断片化・標識

第7章 カスタム抗体市場:種類別

  • イントロダクション
  • モノクローナル抗体
  • ポリクローナル抗体
  • 組換え抗体
  • その他のカスタム抗体

第8章 カスタム抗体市場:供給源別

  • イントロダクション
  • マウス
  • ウサギ
  • その他の供給源

第9章 カスタム抗体市場:用途別

  • イントロダクション
  • 研究
  • 治療

第10章 カスタム抗体市場:適応症別

  • イントロダクション
  • 腫瘍
  • 感染症
  • 免疫
  • 神経生物学
  • 心血管疾患
  • その他の適応症

第11章 カスタム抗体市場:エンドユーザー別

  • イントロダクション
  • 製薬企業・バイオテクノロジー企業
  • 教育・研究機関
  • CRO (医薬品開発業務受託機関)

第12章 カスタム抗体市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • 韓国
    • インド
    • 他のアジア太平洋諸国
  • ラテンアメリカ
    • ブラジル
    • 他のラテンアメリカ諸国
  • 中東・アフリカ

第13章 競合情勢

  • イントロダクション
  • 主要企業が採用した戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • スタートアップ向け企業評価クアドラント (2022年)
  • 企業のフットプリント
  • 企業のサービスフットプリント
  • 企業の地理的フットプリント
  • 市場関係者が採用する主要な戦略

第14章 企業プロファイル

  • 主要企業
    • THERMO FISHER SCIENTIFIC, INC.
    • GENSCRIPT
    • ABCAM PLC.
    • CELL SIGNALING TECHNOLOGY, INC.
    • BIO-RAD LABORATORIES, INC.
    • MERCK KGAA
    • AGILENT TECHNOLOGIES, INC.
    • PERKINELMER, INC.
    • ROCKLAND IMMUNOCHEMICALS, INC.
    • PROMAB BIOTECHNOLOGIES, INC.
    • INNOVAGEN AB
    • ORIGENE TECHNOLOGIES INC.
    • BIO-TECHNE
    • CREATIVE DIAGNOSTICS
    • SINO BIOLOGICAL, INC.
  • その他の企業
    • RAYBIOTECH LIFE, INC.
    • ABBIOTEC, INC.
    • PROSCI INCORPORATED
    • BOSTER BIOLOGICAL TECHNOLOGY
    • CUSABIO TECHNOLOGY LLC
    • BIOINTRON
    • KANEKA EUROGENTEC S.A.
    • CREATIVE BIOLABS
    • ENVIGO
    • IMGENEX INDIA

第15章 付録

目次
Product Code: BT 6817

The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4% during the forecast period. Factors such as increasing investment for the development of ADCs and rising research in structure-based drug design and therapeutics mAbs of custom antibody, are driving the market growth at a faster pace.

"The recombinant antibodies segment is likely to grow at highest CAGR during the forecast period of 2023-2028."

On the basis of type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. The recombinant antibodies segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to low immunogenicity and increased research reproducibility offered by recombinant antibodies. This is likely to have a positive impact on segmental growth.

"The mice source is expected to hold a dominant share in 2023."

Based on the source, the market is segmented into mice, rabbits, and others. The mice segment is expected to grow at a faster pace during the forecast period due to factors that mice are conventionally preferred hosts for mAbs production for research purposes.

"In 2022, the research applications segment held a dominant share."

Based on application, the custom antibody market is segmented into research and therapeutic applications. The research applications segment held a dominant share of the custom antibody market. Adoption of custom antibody in research and drug discovery & development is one of the major factors anticipated to project the market growth

"The oncology segment is likely to grow at highest CAGR during the forecast period of 2023-2028."

Based on indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and others. The oncology indication segment held a dominant share of the custom antibody market, in 2022. The growing use of mAbs and custom antibody in cancer treatment is one of the major factor anticipated to project market growth.

"Asia Pacific region is likely to grow at faster pace."

The custom antibody market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of custom antibody market. The dominance of the region is attributable to various factors such as the presence of dominant and key market players in the region coupled with the ongoing research activities of custom antibody. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising research initiatives undertaken by the government for antibody development in the region, and the emergence of new market players in the custom antibody market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60%, and Demand Side - 40%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific (US)
  • GenScript (China)
  • Abcam plc. (UK)
  • Cell Signaling Technology, Inc (US)
  • Bio-Rad Laboratories, Inc (US)
  • Merck KGaA (Germany)
  • Agilent Technologies, Inc (Germany)
  • PerkinElmer, Inc (US)
  • Rockland Immunochemicals, Inc (US)
  • ProMab Biotechnologies, Inc (US)
  • Innovagen AB (Sweden)
  • OriGene Technologies (US)
  • Bio-Techne (US)
  • Creative Diagnostics (US)
  • Sino Biological, Inc (China)
  • RayBiotech Life, Inc (US)
  • Abbiotec, Inc (US)
  • ProSci (US)
  • Boster Biological Technology (US)
  • CUSABIO Technology LLC (US)
  • Biointron (China)
  • Kaneka Eurogentech S.A. (Belgium)
  • Creative Biolabs (US)
  • Envigo (US)
  • Imgenex India Pvt. Ltd (India).

Research Coverage:

This report provides a detailed picture of the custom antibody market. It aims at estimating the size and future growth potential of the market across different segments, such as service, type, source, application, indication, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 AVERAGE MARKET SIZE ESTIMATION (2022)
    • FIGURE 3 AVERAGE MARKET SIZE ESTIMATION (2022): CUSTOM ANTIBODY MARKET
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.4 GROWTH RATE ASSUMPTIONS
  • 2.5 GROWTH FORECAST
    • FIGURE 6 GROWTH RATE ANALYSIS
  • 2.6 RISK ASSESSMENT
  • 2.7 INSIGHTS FROM PRIMARY EXPERTS
  • 2.8 CUSTOM ANTIBODY MARKET: RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 7 CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028
    • FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2023 VS. 2028
    • FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2023 VS. 2028
    • FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY APPLICATION, 2023 VS. 2028
    • FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY INDICATION, 2023 VS. 2028
    • FIGURE 12 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 VS. 2028
    • FIGURE 13 CUSTOM ANTIBODY MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 CUSTOM ANTIBODY MARKET OVERVIEW
    • FIGURE 14 RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2022)
    • FIGURE 15 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2022)
    • FIGURE 16 MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising research activities and funding investments for antibody development
      • 5.2.1.2 Growing use of custom antibodies in precision medicine
      • 5.2.1.3 Use of antibodies in biomarker identification and validation
      • 5.2.1.4 Quality concerns over catalog antibodies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs and complexities associated with antibody development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
      • 5.2.3.2 Rising therapeutic applications for mAbs
    • FIGURE 19 NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016-2022)
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with immunization of host animals
      • 5.2.4.2 Presence of alternative antibodies
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 20 CUSTOM ANTIBODY MARKET: VALUE-CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
    • FIGURE 21 CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS
    • 5.4.1 ROLE IN ECOSYSTEM
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 DEGREE OF COMPETITION
  • 5.6 PATENT ANALYSIS
    • FIGURE 22 CUSTOM ANTIBODY MARKET: PATENT ANALYSIS
  • 5.7 PRICING ANALYSIS
    • 5.7.1 AVERAGE SELLING PRICE TREND
    • 5.7.2 INDICATIVE PRICING ANALYSIS
    • TABLE 6 SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT
    • TABLE 7 SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC.
    • 5.7.3 INDICATIVE PRICING ANALYSIS, BY REGION
    • TABLE 8 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA
    • TABLE 9 SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US
  • 5.8 TECHNOLOGICAL ANALYSIS
    • 5.8.1 CUSTOM ANTIBODY SERVICES
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 KEY CONFERENCES & EVENTS IN 2023
    • TABLE 11 CUSTOM ANTIBODY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 23 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
    • FIGURE 24 CUSTOM ANTIBODY MARKET: KEY BUYING CRITERIA FOR END USERS
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 25 REVENUE SHIFT AND NEW REVENUE

6 CUSTOM ANTIBODY MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 12 CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
  • 6.2 ANTIBODY DEVELOPMENT
    • TABLE 13 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 14 CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 15 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 16 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 ANTIBODY CHARACTERIZATION
      • 6.2.1.1 Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market
    • TABLE 19 CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 ANTIGEN PREPARATION
      • 6.2.2.1 Development of research antibodies using bioinformatics tools to support market growth
    • TABLE 24 CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
      • 6.2.3.1 Rising demand for therapeutic antibodies to drive market
    • TABLE 29 CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 30 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 ANTIBODY PRODUCTION & PURIFICATION
    • 6.3.1 RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET
    • TABLE 34 CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 ANTIBODY FRAGMENTATION & LABELING
    • 6.4.1 RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH
    • TABLE 39 CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION)

7 CUSTOM ANTIBODY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 44 CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 MONOCLONAL ANTIBODIES
    • 7.2.1 HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET
    • TABLE 45 CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 POLYCLONAL ANTIBODIES
    • 7.3.1 ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE
    • TABLE 50 CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 RECOMBINANT ANTIBODIES
    • 7.4.1 LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET
    • TABLE 55 CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, 2021-2028 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 OTHER CUSTOM ANTIBODIES
    • TABLE 60 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 CUSTOM ANTIBODY MARKET, BY SOURCE

  • 8.1 INTRODUCTION
    • TABLE 65 CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
  • 8.2 MICE
    • 8.2.1 CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE
    • TABLE 66 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 RABBITS
    • 8.3.1 ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET
    • TABLE 71 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER SOURCES
    • TABLE 76 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION)

9 CUSTOM ANTIBODY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 81 CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 RESEARCH
    • 9.2.1 RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET
    • TABLE 82 CUSTOM ANTIBODY MARKET FOR RESEARCH, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 THERAPEUTICS
    • 9.3.1 GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET
    • TABLE 87 CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CUSTOM ANTIBODY MARKET, BY INDICATION

  • 10.1 INTRODUCTION
    • TABLE 92 CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 10.2 ONCOLOGY
    • 10.2.1 GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET
    • TABLE 93 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 94 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 INFECTIOUS DISEASES
    • 10.3.1 WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
    • TABLE 98 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 99 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 IMMUNOLOGY
    • 10.4.1 RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET
    • TABLE 103 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 NEUROBIOLOGY
    • 10.5.1 RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET
    • TABLE 108 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 109 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.6 CARDIOVASCULAR DISEASES
    • 10.6.1 GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET
    • TABLE 113 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 114 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.7 OTHER INDICATIONS
    • TABLE 118 CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 119 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 120 EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

11 CUSTOM ANTIBODY MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 123 CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 124 CUSTOM ANTIBODY MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 125 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET
    • TABLE 129 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET
    • TABLE 134 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 138 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 CONTRACT RESEARCH ORGANIZATIONS
    • 11.4.1 ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH
    • TABLE 139 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 140 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 EUROPE: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 143 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

12 CUSTOM ANTIBODY MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 144 CUSTOM ANTIBODY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 26 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
    • TABLE 145 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 146 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 147 NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 150 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 152 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 Rising research in structure-based drug design and therapeutic mAbs to drive market
    • TABLE 153 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 154 US: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 157 US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 158 US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 159 US: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 Increasing genomic research to fuel market uptake
    • TABLE 160 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 161 CANADA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 164 CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 165 CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 166 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.3 NORTH AMERICA: RECESSION IMPACT
  • 12.3 EUROPE
    • TABLE 167 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 169 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 170 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 172 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 173 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 174 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 High investments in development of ADCs to drive market
    • TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 176 GERMANY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 179 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 180 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 181 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market
    • TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 183 UK: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 185 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 186 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 187 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 188 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth
    • TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 190 FRANCE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 193 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 194 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 195 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.4 ITALY
      • 12.3.4.1 Increasing research activities in proteomics & genomics to drive market
    • TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 197 ITALY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 198 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 199 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 200 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 201 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 202 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.5 SPAIN
      • 12.3.5.1 Growing focus on advancements in personalized medicine to support market growth
    • TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 204 SPAIN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 205 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 206 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 207 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 208 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 209 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 211 REST OF EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 213 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 214 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 215 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 216 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.7 EUROPE: RECESSION IMPACT
  • 12.4 ASIA PACIFIC
    • FIGURE 27 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
    • TABLE 217 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 218 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 219 ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 220 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 221 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 222 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 223 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 224 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.1 JAPAN
      • 12.4.1.1 Rising research activities for development of ADCs to drive market
    • TABLE 225 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 226 JAPAN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 227 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 228 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 229 JAPAN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 230 JAPAN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 231 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.2 CHINA
      • 12.4.2.1 Increasing establishment of R&D facilities to fuel uptake
    • TABLE 232 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 233 CHINA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 234 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 235 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 236 CHINA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 237 CHINA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 238 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.3 SOUTH KOREA
      • 12.4.3.1 Increasing research on therapeutic antibodies and cytokines to support market growth
    • TABLE 239 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 240 SOUTH KOREA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 241 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 242 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 243 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 244 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 245 SOUTH KOREA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 High pharmaceutical R&D spending to support market growth
    • TABLE 246 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 247 INDIA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 248 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 249 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 250 INDIA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 251 INDIA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 252 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.5 REST OF ASIA PACIFIC
    • TABLE 253 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 254 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 255 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 256 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 257 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 258 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 259 REST OF ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 12.5 LATIN AMERICA
    • TABLE 260 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 261 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 262 LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 263 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 264 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 265 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 266 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 267 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.1 BRAZIL
      • 12.5.1.1 Utilization of therapeutic antibodies for oncology applications to support market growth
    • TABLE 268 BRAZIL: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 269 BRAZIL: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 270 BRAZIL: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 271 BRAZIL: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 272 BRAZIL: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 273 BRAZIL: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 274 BRAZIL: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.2 REST OF LATIN AMERICA
    • TABLE 275 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 276 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 277 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 278 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 279 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 280 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 281 REST OF LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.3 LATIN AMERICA: RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 INCREASING RESEARCH COLLABORATIONS AND DEVELOPING HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • TABLE 282 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 283 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 284 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 285 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 286 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 287 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 288 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 28 CUSTOM ANTIBODY MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 29 CUSTOM ANTIBODY MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022)
    • TABLE 289 CUSTOM ANTIBODY MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 13.5 COMPANY EVALUATION QUADRANT
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 30 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION QUADRANT
  • 13.6 COMPANY EVALUATION QUADRANT FOR STARTUPS (2022)
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 STARTING BLOCKS
    • 13.6.3 RESPONSIVE COMPANIES
    • 13.6.4 DYNAMIC COMPANIES
    • FIGURE 31 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS (2022)
  • 13.7 COMPANY FOOTPRINT
  • 13.8 COMPANY SERVICE FOOTPRINT
    • TABLE 290 CUSTOM ANTIBODY MARKET: SERVICE PORTFOLIO ANALYSIS (2022)
  • 13.9 COMPANY GEOGRAPHIC FOOTPRINT
    • TABLE 291 CUSTOM ANTIBODY MARKET: GEOGRAPHIC REVENUE MIX (2022)
  • 13.10 KEY STRATEGIES ADOPTED BY MARKET PLAYERS
    • 13.10.1 CUSTOM ANTIBODY MARKET: KEY DEALS (JANUARY 2020 TO JANUARY 2023)
    • 13.10.2 CUSTOM ANTIBODY MARKET: KEY EXPANSIONS (JANUARY 2020 TO JANUARY 2023)

14 COMPANY PROFILES

(Business overview, Services offered, Recent developments, Other developments & MnM View)*

  • 14.1 KEY MARKET PLAYERS
    • 14.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 292 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • TABLE 293 THERMO FISHER SCIENTIFIC, INC.: DEALS
    • 14.1.2 GENSCRIPT
    • TABLE 294 GENSCRIPT: BUSINESS OVERVIEW
    • FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2021)
    • TABLE 295 GENSCRIPT: DEALS
    • 14.1.3 ABCAM PLC.
    • TABLE 296 ABCAM PLC.: BUSINESS OVERVIEW
    • FIGURE 34 ABCAM PLC.: COMPANY SNAPSHOT (2021)
    • TABLE 297 ABCAM PLC.: DEALS
    • 14.1.4 CELL SIGNALING TECHNOLOGY, INC.
    • TABLE 298 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
    • 14.1.5 BIO-RAD LABORATORIES, INC.
    • TABLE 299 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 14.1.6 MERCK KGAA
    • TABLE 300 MERCK KGAA.: BUSINESS OVERVIEW
    • FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2021)
    • TABLE 301 MERCK KGAA: DEALS
    • 14.1.7 AGILENT TECHNOLOGIES, INC.
    • TABLE 302 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
    • 14.1.8 PERKINELMER, INC.
    • TABLE 303 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
    • 14.1.9 ROCKLAND IMMUNOCHEMICALS, INC.
    • TABLE 304 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
    • TABLE 305 ROCKLAND IMMUNOCHEMICALS, INC.: DEALS
    • 14.1.10 PROMAB BIOTECHNOLOGIES, INC.
    • TABLE 306 PROMAB BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • 14.1.11 INNOVAGEN AB
    • TABLE 307 INNOVAGEN AB: BUSINESS OVERVIEW
    • 14.1.12 ORIGENE TECHNOLOGIES INC.
    • TABLE 308 ORIGENE TECHNOLOGIES INC.: BUSINESS OVERVIEW
    • 14.1.13 BIO-TECHNE
    • TABLE 309 BIO-TECHNE: BUSINESS OVERVIEW
    • FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT (2021)
    • TABLE 310 BIO-TECHNE: DEALS
    • 14.1.14 CREATIVE DIAGNOSTICS
    • TABLE 311 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
    • 14.1.15 SINO BIOLOGICAL, INC.
    • TABLE 312 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
    • FIGURE 40 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT (2021)

Details on Business overview, Services offered, Recent developments, Other developments & MnM View might not be captured in case of unlisted companies.

  • 14.2 OTHER PLAYERS
    • 14.2.1 RAYBIOTECH LIFE, INC.
    • 14.2.2 ABBIOTEC, INC.
    • 14.2.3 PROSCI INCORPORATED
    • 14.2.4 BOSTER BIOLOGICAL TECHNOLOGY
    • 14.2.5 CUSABIO TECHNOLOGY LLC
    • 14.2.6 BIOINTRON
    • 14.2.7 KANEKA EUROGENTEC S.A.
    • 14.2.8 CREATIVE BIOLABS
    • 14.2.9 ENVIGO
    • 14.2.10 IMGENEX INDIA

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS